| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Benzotript targets cholecystokinin receptors (CCK) and gastrin receptors. It acts as a competitive antagonist, inhibiting the binding and actions of endogenous ligands CCK and gastrin. In gastrointestinal smooth muscle, it has an IC₅₀ of 52.5-58.4 μM. Unlike devazepide, benzotript also interacts with mu, delta, and kappa opioid binding sites. It is one of the few commercially available probes targeting the 78-kDa gastrin-binding protein (GBP). By blocking CCK and gastrin receptors, benzotript modulates gastrointestinal functions, enzyme secretion, and cell proliferation pathways.
|
|---|---|
| ln Vitro |
In vitro, benzotript shows antiproliferative effects in human colon carcinoma cell lines. It is a competitive antagonist of both cholecystokinin (CCK) and gastrin receptors. In isolated rabbit gastric fundic parietal cells, benzotript (along with proglumide) inhibits acid output. The compound is a validated reference standard for pancreatic acini amylase secretion and organ bath assays. Benzotript's antiproliferative effects make it a valuable tool for studying the role of CCK and gastrin in cancer cell growth.
|
| ln Vivo |
In vivo, benzotript has been studied for its effects on gastrointestinal function and cell proliferation. As a CCK and gastrin receptor antagonist, it modulates gastrointestinal functions, enzyme secretion, and cell proliferation pathways. However, detailed in vivo efficacy data in animal models are limited. The compound is primarily used as a research tool in in vitro studies of CCK/gastrin pathways. For in vivo formulation, benzotript can be dissolved in appropriate vehicles. Comprehensive in vivo pharmacokinetic and pharmacodynamic studies are needed.
|
| Enzyme Assay |
In vitro receptor binding assays for benzotript involve measuring its binding affinity to cholecystokinin (CCK) and gastrin receptors. Membrane preparations from tissues expressing CCK or gastrin receptors are incubated with a radiolabeled ligand (e.g., [³H]CCK or [¹²⁵I]gastrin) and varying concentrations of benzotript. The displacement of the radiolabeled ligand is measured, and the IC₅₀ or Ki value is calculated. The compound's competitive antagonism is confirmed by Schild analysis. These assays confirm benzotript's mechanism as a dual CCK/gastrin receptor antagonist.
|
| Cell Assay |
In vitro cell-based assays for benzotript evaluate its antiproliferative effects in human colon carcinoma cell lines. Cells are cultured in appropriate media and treated with serial dilutions of benzotript. Cell proliferation is assessed using MTT, BrdU incorporation, or cell counting assays. The compound's effects on CCK- or gastrin-stimulated cell proliferation are measured. In isolated rabbit gastric fundic parietal cells, acid output is measured using the [¹⁴C]aminopyrine (AP) accumulation method. These assays confirm the compound's functional activity as a CCK/gastrin receptor antagonist.
|
| Animal Protocol |
In vivo animal experiments for benzotript have not been extensively reported. The compound is primarily used as a research tool in in vitro studies of CCK/gastrin pathways. For potential in vivo studies, benzotript can be administered orally or via intraperitoneal injection in animal models of gastrointestinal disorders or cancer. The compound is soluble in DMSO and can be formulated in appropriate vehicles for administration. Pharmacodynamic endpoints would include assessment of gastric acid secretion, pancreatic enzyme secretion, and tumor growth. Comprehensive in vivo studies are needed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) data for benzotript are limited. The compound has a molecular weight of 342.78 g/mol and is a solid powder. It has a solubility of >51.4 μg/mL at pH 7.4. The compound should be stored dry, in the dark, at 0-4°C for short-term use (days to weeks) or at -20°C for long-term storage (months to years). Comprehensive ADME studies, including absorption, distribution, metabolism, and excretion, are not well-characterized. For research use only, not for human therapeutic use.
|
| Toxicity/Toxicokinetics |
The toxicity profile of benzotript has not been extensively characterized. As a research compound, it should be handled with appropriate safety precautions in the laboratory. The compound is for research use only and is not intended for human or veterinary use. Standard safety precautions for handling chemical compounds should be followed, including working in a well-ventilated area and using appropriate personal protective equipment. Comprehensive toxicological studies are needed to fully characterize the safety profile of benzotript.
|
| References |
|
| Additional Infomation |
Benzotript (N-p-chlorobenzoyl-L-tryptophan) is a non-peptide, competitive antagonist of both cholecystokinin (CCK) and gastrin receptors. It is a small molecule derived from tryptophan and belongs to a distinct pharmacological class of CCK receptor antagonists. Benzotript shows antiproliferative effects in human colon carcinoma cell lines. It is one of the few commercially available probes targeting the 78-kDa gastrin-binding protein (GBP). Benzotript is a validated reference standard for pancreatic acini amylase secretion and organ bath assays. It is a research tool for studying CCK/gastrin pathways and has not progressed to clinical trials.
|
| Molecular Formula |
C18H15CLN2O3
|
|---|---|
| Molecular Weight |
342.7763
|
| Exact Mass |
342.077
|
| CAS # |
39544-74-6
|
| PubChem CID |
2060890
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
643.7ºC at 760 mmHg
|
| Flash Point |
343.1ºC
|
| LogP |
3.637
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
24
|
| Complexity |
465
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
ClC1=CC=C(C(NC(CC2=CNC3=CC=CC=C23)C(=O)O)=O)C=C1
|
| InChi Key |
QJERBBQXOMUURJ-INIZCTEOSA-N
|
| InChi Code |
InChI=1S/C18H15ClN2O3/c19-13-7-5-11(6-8-13)17(22)21-16(18(23)24)9-12-10-20-15-4-2-1-3-14(12)15/h1-8,10,16,20H,9H2,(H,21,22)(H,23,24)/t16-/m0/s1
|
| Chemical Name |
(2S)-2-[(4-chlorobenzoyl)amino]-3-(1H-indol-3-yl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9173 mL | 14.5866 mL | 29.1732 mL | |
| 5 mM | 0.5835 mL | 2.9173 mL | 5.8346 mL | |
| 10 mM | 0.2917 mL | 1.4587 mL | 2.9173 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
